My blood pressure normalization journey — what worked for you?

tane_welly said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

tane_welly said:

...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

Dr.ReproEndo said:

tane_welly said: ...we don't know the long-term effects of cardiovascular risk...

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 11 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 50" → 34" ✅ Resolved
2. Triglycerides: 228 → 108 ✅ Resolved
3. HDL: 34 → 60 ✅ Resolved
4. Blood pressure: 148/90 → 121/75 ✅ Resolved
5. Fasting glucose: 123 → 86 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

tane_welly said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

Clinical perspective, offered as context rather than as advice.

tane_welly said:

...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

• Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
• Published in NEJM, JAMA, Lancet (not press releases)
• Replicated across multiple independent research groups
• Proven cardiovascular and renal benefits beyond weight loss
• Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.